Each WFH eLearning Program consists of a series of educational modules designed for individual self-directed or small-group learning. Educational content about hemophilia and other bleeding disorders is brought to life with detailed colour illustrations, interactive features, a glossary of terms, and linked resources for further reading. There are even quizzes, and progress checks so that you can evaluate whether you have fully understood the content. You can work through an entire module or look up sections of particular interest in the interactive table of contents.
The Treatment Products eLearning Program explores the basics of bleeding disorders and the products and techniques used to treat them in 4 interactive modules:
This module explains how blood clots and the coagulation cascade, what goes wrong in factor deficiency, and how factor replacement therapy works by correcting this.
Explore the evolution of products for the treatment of bleeding disorders, how each type of product provided a breakthrough in care, and the accompanying advances in safety each delivered.
This module explains the principles of gene expression and transfer that underly gene therapy, how efficacy and safety are being investigated, and the need for lifelong follow up.
The WFH Treatment Guidelines eLearning Program explores the WFH Guidelines for the Management of Hemophilia, 2nd edition, in 6 dynamic illustrated eLearning modules, in English, French, and Spanish. Target factor peak level recommendations are included for contexts with and without significant resource constraints.
This module looks at principles of care, comprehensive care, fitness and physical activity, prophylaxis, home therapy, monitoring health status and outcomes, pain management, surgery and invasive procedures, and dental care and management.
This module explores the issues of carriers, genetic testing and counselling, prenatal diagnosis, childbirth, vaccinations, psychosocial issues, sexuality, and ageing for people with hemophilia.
This module focuses on the principles of diagnosis, as well as the technical aspects, equipment, and reagents involved in coagulation laboratory testing for bleeding disorders.
FVIII and FIX clotting factor concentrates, fresh frozen plasma, cryoprecipitate, and other pharmacological options including DDAVP, tranexamic acid, and epsilon aminocaproic acid are presented in this module.
This module presents the WFH recommendations regarding the treatment of specific hemorrhages including into muscles, joints, soft tissues, and internal organs, as well as head trauma, lacerations, abrasions, and nosebleeds, in people with hemophilia.
This module discusses the management of inhibitors, as well as musculoskeletal and infection-related complications.
The Clinical Advances in Gene Therapy for Hemophilia continuing medical education (CME) curriculum was designed for clinicians and provides introductory information on gene therapy in hemophilia. Over this series of five online activities, clinicians can qualify for CME credits, while all learners can obtain a completion certificate or enhance their knowledge of gene therapy in hemophilia. The curriculum was developed in collaboration with the National Hemophilia Foundation (NHF), the European Haemophilia Consortium (EHC), and Medscape Education. UPDATE: The Science of Gene Therapy and Why Gene Therapy for Hemophilia? modules have been re-certified for CME credits, expiring September 6, 2020!
This self-assessment survey allows learners to see how much they already know about gene therapy in hemophilia, and the answers explain the essential information required for a fuller understanding.
This round table video discussion presents three experts who reflect on the evolution of gene therapy in hemophilia, including its development, ongoing research, and current and future uses.
In this video commentary one expert take an in-depth look at the vector technology behind early clinical trials and emerging approaches to gene therapy in hemophilia.
In this video discussion two experts consider the advantages, disadvantages, and unknowns of gene therapy in hemophilia, and the potential for this technology in countries with limited resources.
This clinical article takes learners on a deep dive into the recent early phase gene therapy clinical trials in hemophilia that have paved the way for the current pivotal phase 3 studies.
Updated September 2018